Trial Profile
A longitudinal observational follow-up of the PRECEPT [Parkinson Research Examination of CEP-1347 Trial] study cohort
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Oct 2016
Price :
$35
*
At a glance
- Drugs CEP 1347 (Primary)
- Indications Parkinson's disease
- Focus Biomarker; Therapeutic Use
- Acronyms PostCEPT
- 01 Mar 2008 New trial record.